Thymalin, Epithalamin and Vilon after complicated appendicitis
B. I. Kuznik, Kh. R. Abdulaev, Yu. A. Vitkovsky, I. D. Likhanov, M. N. Tsybikov, N. N. Tsybikov · 2008 · Medical Immunology. 2008;10(4–5):455–462.
Reported findings and study design
Comparison of standard care and peptide adjuncts after postoperative wound infection. The paper measured serum cytokines by immunoassay and compared immune markers before and after treatment.
Dose, route and schedule
Standard care included abscess drainage, antibiotics and symptomatic treatment. The reported adjuncts were intramuscular Thymalin or Epithalamin at 10 mg per injection for 10 days, or Vilon at 10 µg per injection for five or ten days.
Protocol source ↗ · Original article, pp. 455–456
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean hospitalization | 24.2 days with standard care versus 18.0–19.0 days with peptide adjuncts | Unadjusted group means from five small, unequal groups. |
| TNF-α in the Vilon cytokine subset | 447 ± 20 to 115 ± 9 pg/mL (n = 25) | Within-group p < 0.001 in Table 3 |
| IL-8 | Rose in all four cytokine groups, including standard care. | |
| Wound closure and safety | The authors described primary wound healing. No arm-level wound-healing rate or systematic adverse-event table was recovered. |
Reported hospital stay by treatment group
| Group | Patients | Mean days ± reported uncertainty | Difference from standard care |
|---|---|---|---|
| Standard care | 10 | 24.2 ± 0.6 | Reference |
| Thymalin | 10 | 19.0 ± 0.7 | 5.2 days shorter |
| Epithalamin | 12 | 18.0 ± 0.6 | 6.2 days shorter |
| Vilon, five days | 30 | 18.8 ± 0.6 | 5.4 days shorter |
| Vilon, ten days | 10 | 19.0 ± 0.5 | 5.2 days shorter |
Differences are calculated from published means. The paper does not clearly identify the contrast for the p-values printed alongside these means.
Table 3: serum cytokines before → after treatment
| Cytokine (pg/mL) | Healthy reference | Standard care (n = 10) | Thymalin (n = 10) | Epithalamin (n = 12) | Vilon (n = 25) |
|---|---|---|---|---|---|
| TNF-α | 13 ± 4 | 432 ± 32 → 389 ± 25 | 396 ± 28 → 186 ± 21 | 486 ± 28 → 205 ± 19 | 447 ± 20 → 115 ± 9 |
| IL-8 | 18 ± 5 | 126 ± 18 → 678 ± 31 | 146 ± 20 → 383 ± 24 | 159 ± 19 → 453 ± 28 | 175 ± 16 → 418 ± 25 |
| IL-1α | 12 ± 3 | 105 ± 28 → 88 ± 15 | 123 ± 21 → 58 ± 12 | 135 ± 20 → 87 ± 14 | 131 ± 11 → 52 ± 6 |
| IL-1β | 8 ± 2 | 368 ± 24 → 142 ± 19 | 326 ± 23 → 245 ± 24 | 310 ± 22 → 318 ± 25 | Not reported |
Mean ± standard error as labeled in the PDF. TNF-α within-group p > 0.05 with standard care and p < 0.001 in each adjunct group. Vilon’s cytokine subset is distinct from its 40-person hospital-stay comparison. Values follow the original PDF text where digital transcriptions disagree.
Vilon showed the largest within-group TNF-α decrease. Hospitalization means were close among the four adjunct groups. Neither outcome establishes a comparative treatment effect.
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Small, unequal groups and unclear treatment assignment leave confounding unresolved. The article does not establish that Vilon was superior or equivalent to the other adjuncts.
- The Vilon hospital groups totaled 40. The cytokine table included 25, with no breakdown by treatment duration.
- The hospitalization paragraph prints p < 0.01 after each mean without clearly specifying a contrast. No systematic adverse-event table or quantified wound-healing rates were recovered.
Source access
Original journal PDF text, methods and Tables 1 and 3 checked. The 321st District Military Clinical Hospital in Chita was an author affiliation.
Source reviewed 2026-11-10.
Source type: Original clinical journal article
Citation and original source
Original source: B. I. Kuznik, Kh. R. Abdulaev, Yu. A. Vitkovsky, I. D. Likhanov, M. N. Tsybikov, N. N. Tsybikov. Thymalin, Epithalamin and Vilon after complicated appendicitis Medical Immunology. 2008;10(4–5):455–462. 2008.
Molekul research summary: https://molekul.io/research/kuznik-thymalin-epithalamin-vilon-2008. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymalin
Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.
Epithalamin
A pineal-gland tissue extract containing a mixture of peptides. Human aging and melatonin studies of this preparation must be distinguished from research on synthetic Epitalon (AEDG).
Vilon
Defined Lys–Glu (KE) dipeptide with historical adjunct-treatment reports in type 1 diabetes and separate laboratory research. Immune and coagulation-marker findings do not establish autoimmune disease modification.